Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial

Inflamm Bowel Dis. 2022 Oct 3;28(10):e143. doi: 10.1093/ibd/izac066.

Authors

Affiliations

¹ Genentech, Inc., South San Francisco, CA, USA.
² Roche Products Limited, Welwyn Garden City, United Kingdom.
³ Children's Memorial Health Institute, Warsaw, Poland.
⁴ University of Rzeszów, Rzeszów, Poland.

No abstract available

Publication types

Published Erratum

Grants and funding

F. Hoffmann-La Roche, Inc.